Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Short term Debt (2022 - 2025)

PAVmed has reported Short term Debt over the past 4 years, most recently at $11.1 million for Q4 2025.

  • Quarterly results put Short term Debt at $11.1 million for Q4 2025, down 61.86% from a year ago — trailing twelve months through Dec 2025 was $11.1 million (down 61.86% YoY), and the annual figure for FY2025 was $11.1 million, down 61.86%.
  • Short term Debt for Q4 2025 was $11.1 million at PAVmed, up from $6.9 million in the prior quarter.
  • Over the last five years, Short term Debt for PAVM hit a ceiling of $45.5 million in Q1 2024 and a floor of $260000.0 in Q2 2023.
  • Median Short term Debt over the past 4 years was $29.5 million (2022), compared with a mean of $26.2 million.
  • Biggest five-year swings in Short term Debt: plummeted 99.12% in 2023 and later surged 16823.08% in 2024.
  • PAVmed's Short term Debt stood at $33.6 million in 2022, then soared by 31.35% to $44.2 million in 2023, then plummeted by 34.16% to $29.1 million in 2024, then plummeted by 61.86% to $11.1 million in 2025.
  • The last three reported values for Short term Debt were $11.1 million (Q4 2025), $6.9 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.